Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Rhea-AI Summary

Exelixis, Inc. (Nasdaq: EXEL) will participate in fireside chats at investor conferences in May, including BofA Securities Health Care Conference, Citizens JMP Life Sciences Conference, and RBC Capital Markets Global Healthcare Conference. The presentations will be webcast on www.exelixis.com with replay options available for at least 30 days.

Positive

• Participation in high-profile investor conferences enhances visibility and awareness among potential investors.

• Webcasting the presentations increases accessibility to a wider audience, potentially attracting new investors.

Negative

• There may be impact on stock price if the content of the fireside chats does not address key investor concerns or fail to impress potential investors.

- Presentations to be webcast on www.exelixis.com -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:

• BofA Securities 2024 Health Care Conference: Exelixis is scheduled to present at 2:20 p.m. ET / 11:20 a.m. PT on Tuesday, May 14 in Las Vegas.
• Citizens JMP Life Sciences Conference: Exelixis is scheduled to present at 9:30 a.m. ET / 6:30 a.m. PT on Tuesday, May 14 in New York City.
• RBC Capital Markets 2024 Global Healthcare Conference: Exelixis is scheduled to present at 2:35 p.m. ET / 11:35 a.m. PT on Tuesday, May 14 in New York City.

To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX^® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507174596/en/

Investors Contact:

Varant Shirvanian

Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

When will Exelixis participate in fireside chats at investor conferences in May?

Exelixis will participate in fireside chats at investor conferences in May, including BofA Securities Health Care Conference, Citizens JMP Life Sciences Conference, and RBC Capital Markets Global Healthcare Conference.

Where can I access the webcast links for the presentations?

To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading.

Will replays be available for the webcasts?

Replays will be available at the same location for at least 30 days after the presentations.